Generating a pneumococcal vaccine that is serotype independent and cost effective remains a global challenge. γ -Irradiation has been used widely to sterilize biological products. It can also be utilized as an inactivation technique to generate whole-cell bacterial and viral vaccines with minimal impact on pathogen structure and antigenic determinants. In the present study, we utilized γ -irradiation to inactivate an un-encapsulated Streptococcus pneumoniae strain Rx1 with an unmarked deletion of the autolysin gene lytA and with the pneumolysin gene ply replaced with an allele encoding a non-toxic pneumolysoid (PdT) (designated γ -PN vaccine). Intranasal vaccination of C57BL/6 mice with γ -PN was shown to elicit serotype-independent protection in lethal challenge models of pneumococcal pneumonia and sepsis. Vaccine efficacy was shown to be reliant on B-cells and interleukin (IL)-17A responses. Interestingly, immunization promoted IL-17 production by innate cells not T helper 17 (Th17) cells. These data are the first to report the development of a non-adjuvanted intranasal γ -irradiated pneumococcal vaccine that generates effective serotype-independent protection, which is mediated by both humoral and innate IL-17 responses.
INTRODUCTION
Streptococcus pneumoniae (the pneumococcus) is one of the most challenging upper respiratory pathogens of humans, known to be the leading cause of otitis media, pneumonia, bacteraemia and meningitis [1] . It is also a common component of the nasopharyngeal microflora, and it is estimated that S. pneumoniae is carried asymptomatically by approximately 60 % of the population, with carriage rates higher among children under 6 years old [2] . Generally, factors such as an immuno-compromised host and coinfection with other pathogens trigger progression of asymptomatic infection into invasive disease. There are at least 1.2 million childhood deaths associated with S. pneumoniae per year, exem-Abbreviations: CFU, colony forming units; CPS, capsular polysaccharide; IFN-γ , interferon-γ ; IL, interleukin; Lm, Listeria monocytogenes; LytA, autolysin; PdT, pneumolysoid; PspA, pneumococcal surface protein A; Th17, T helper 17 cell; TRM, tissue resident memory; WT, wild type; γ -PN, γ -irradiated Streptococcus pneumoniae; γ δT17, IL-17 + γ δT-cells. 1 Present address: School of Animal and Veterinary Sciences, The University of Adelaide, SA 5005, Australia. 2 These authors contributed equally to this work.
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plifying the severity of pneumococcal disease on a global scale [1, 3] .
The capsular polysaccharides (CPS) are considered the major virulence factor of S. pneumoniae and have been the primary target for vaccination. Given the extensive number of S. pneumoniae capsular serotypes (93 identified to date), the ability to manufacture a universal pneumococcal vaccine remains a substantial challenge. One of the first pneumococcal vaccines licensed was the polyvalent polysaccharide vaccine, which covered initially 14, and later 23 of the most common circulating serotypes [4] . This vaccine is immunogenic in adults and children older than 5 years, but is poorly immunogenic in children less than 5 years old [5] . Lack of protection in younger children was related to the type of immune response induced by CPS based vaccines, as CPS are T-cell-independent antigens and do not induce robust long-term humoral memory. These limitations led to development of pneumococcal conjugate vaccines, whereby the CPS is conjugated to a protein carrier to promote induction of T-celldependent immunity. These preparations elicit strong immunity in infants and young children [6] . The most recent conjugate vaccine (Prevnar 13) covers serotypes and has been in routine use since 2010. However, current formulations are limited in their serotype coverage, which has increased prevalence of disease caused by non-vaccine serotypes, a phenomenon known as 'serotype replacement'. In addition, high cost and limited technology restricts the number of serotypes that can be included in existing vaccine combinations [1, 7] .
In light of existing scientific challenges associated with pneumococcal disease, there is a clear need to develop serotypeindependent pneumococcal vaccines. Whole un-encapsulated bacterial cells, as opposed to selected antigens, have recently been proposed as serotype-independent vaccine candidates [8] . Serotype-independent protection has been related to the induction of protective T helper 17 (Th17) cell-derived interleukin (IL)-17 responses. In fact, the importance of IL-17 responses in vaccine efficacy is becoming more apparent and has also been demonstrated for other pneumococcal vaccines [9] [10] [11] [12] . However, common approaches for inactivation of whole cell-based vaccines include heat or ethanol treatment. Generally, both of these methods have been reported to affect membrane integrity of bacterial cells and subsequently impact vaccine immunogenicity [13, 14] . Therefore, alternative inactivation methods are required to maintain pneumococcal antigens in their native form and to enhance vaccine immunogenicity.
We have been investigating the possibility of using γirradiation to inactivate pathogens for vaccine purposes [15] . γ -Irradiation involves the use of high frequency electromagnetic radiation referred to as 'γ -rays', and has been used world-wide as a form of sterilization for food [16] and pharmaceuticals [17] , and to inactivate highly infectious agents such as Ebola, Marburg and Lassa viruses [18] . γ -Irradiation has also been adopted as an inactivation method for both viral and bacterial vaccines due to reduced structural damage to antigenic epitopes and the ability to induce protective immune responses [14, 19, 20] . In the present study, we utilized γ -irradiation to inactivate an un-encapsulated whole-cell S. pneumoniae strain Rx1. We have also deleted the autolysin gene (lytA) and replaced the pneumolysin gene (ply) with an allele encoding a non-toxic pneumolysoid (PdT). LytA is responsible for cell lysis during growth of pneumococcal cells, whereas Ply is a pore forming toxin that plays many roles in S. pneumoniae pathogenesis including a major role in immune evasion (see review [1] ). Highly concentrated stocks of the engineered pneumococcus were inactivated using γ -irradiation and used as a vaccine [designated γ -irradiated S. pneumoniae (γ -PN)]. In the present study, we demonstrate that intranasal vaccination with non-adjuvanted γ -PN vaccine induces serotypeindependent protection against lethal intranasal challenge models of focal pneumonia and sepsis. Using gene-deficient mice and neutralizing antibody approaches, we show that serotypeindependent protection elicited by γ -PN is dependent on B-cell and IL-17 responses. Notably, γ -PN vaccination does not induce circulating or tissue-resident memory Th17 cell responses, indicating that adaptive IL-17 responses does not account for IL-17mediated protection. Instead, we demonstrate that γ -PN vaccination promotes innate γ δT-cell-derived IL-17A (γ δT17) responses upon live S. pneumoniae challenge. Overall, the present study illustrates the possibility of using intranasal vaccination with a non-adjuvanted γ -PN vaccine to induce serotype-independent protection against lethal pneumococcal pneumonia and sepsis.
MATERIALS AND METHODS

Bacterial strains and growth conditions
S. pneumoniae strains used in the study have been previously described [21] . D39 (serotype 2) EF3030 (serotype 19F) and P9 (serotype 6A) were grown statically at 37 • C in 5 % CO 2 in serum broth (SB) to D 600 of 0.18, as previously described [21] . Strain Rx1 (capsule-negative strain derived from parent strain D39) and its various isogenic mutant derivatives were grown statically in Todd-Hewitt broth supplemented with 0.5 % yeast extract (THY) at 37 • C in 5% CO 2 to D 600 of 0.5, as previously described [22] .
Construction of Rx1[PdT/ LytA] vaccine
Genetic manipulation was performed on strain Rx1 to delete the autolysin gene (lytA) in-frame, and replace the pneumolysin gene (ply) with a derivative encoding PdT (a non-cytolytic toxoid with three amino acid substitutions: Asp 385 → asparagine, Cys 428 → glycine and Trp 433 → phenylalanine), essentially as previously described [23] . All PCR primers used are listed in Supplementary  Table S1 . Firstly, an Rx1 Ply strain was constructed by replacing the Rx1 ply open reading frame with an erythromycin resistance (erm r ) cassette by transformation [23] . The erm r cassette contains the 5 and 3 flanking regions of ply fused to the 5 and 3 termini, respectively, of the erm r gene. The 5 flanking region of ply was obtained by PCR using primers PlyFlankF and PlyEryX, whereas the 3 flanking region was obtained using primers Ply-FlankR and PlyEryY. The erm r gene was PCR amplified using primers J214 and J215. Overlap extension PCR [24] using the above three PCR products was then performed to generate the cassette, which was used to transform Rx1, generating Rx1 Ply. The erm r gene in this construct was then replaced with pdT by transformation with a PdT cassette comprising the PdT open reading frame flanked by ply 5 and 3 flanking regions. Assembly of this cassette involved PCR amplification of ply 5 and 3 flanking regions using PlyFlankF and PlyRevX, and PlyForY and Ply-FlankR, respectively. The pdT gene was obtained by PCR amplification of a PdT-expressing derivative of S. pneumoniae D39 [25] using PdTcloneF and PdTcloneR. The three components of the cassette were then fused and amplified by overlap extension PCR and used to transform Rx1 Ply, generating Rx1[PdT].
A similar strategy was then used to delete the lytA gene from Rx1 [PdT] . First, a tagged lytA deletion mutant was generated by transformation with a cassette comprising a spectinomycin resistance gene (spec r ) fused to lytA 5 and 3 flanking regions. The 5 flanking region of lytA was obtained by PCR using primers LytAFlankF and LytAspecX, whereas the 3 flanking region was obtained using primers LytAFlankR and LytAspecY. The spec r (aad9) gene was PCR amplified using primers J253 and J254. The cassette was then assembled and amplified by overlap extension PCR and used to transform Rx1 [PdT] . The spec r gene was then removed from the resultant Rx1[PdT/ LytA::spec r ] construct by transformation with an overlap extension PCR product that fused the lytA 5 and 3 flanking regions, thereby deleting the lytA gene in-frame. The 5 flanking region of lytA was obtained by PCR using primers LytAFlankF and LytANullA, whereas the 3 region was obtained using primers LytAFlankR and LytANullB. The two fragments were fused and amplified by overlap extension PCR using the two outer primers, and then used to transform Rx1[PdT/ LytA::spec r ]. The final Rx1[PdT/ LytA] construct was validated by PCR, DNA sequencing, Western blotting and a haemolysis assay.
Generation of the γ -irradiated Rx1[PdT/ LytA] vaccine
The Rx1[PdT/ LytA] vaccine strain was first grown in THY as described above, and centrifuged at 4000 × g for 10 min at 4 • C to collect the cells, which were then resuspended in PBS with 10 % glycerol at a density of 1 × 10 10 colony forming units (CFU)/ml. Two hundred micolitre volumes were aliquoted into 1.5 ml cryovials and frozen at −80 • C. Vials containing the concentrated Rx1[PdT/ LytA] vaccine were despatched on dry ice to the Australian Nuclear Science and Technology Organization (ANSTO, Lucas Heights, NSW). The cells were inactivated by exposure to a 60 Co γ -irradiation source and received a dose of 12 kilo-Gray (kGy). The cells were kept frozen on dry ice during the γirradiation process. The resultant γ -irradiated Rx1[PdT/ LytA] vaccine, designated 'γ -PN' was transported to the University of Adelaide on dry ice and stored at −80 • C, until used. To confirm complete inactivation of cells, a sample of γ -PN was thawed, plated out on to blood agar plates and grown overnight at 37 • C in 5 % CO 2 .
Western blotting
Western blotting was performed essentially as described previously [26] . The en-capsulated strain D39, the parent Rx1 strain and the vaccine strain Rx1[PdT/ LytA (pre-irradiation) were grown to approximately 2 × 10 8 CFU/ml and lysates from 20 ml aliquots were analysed. After the transfer, the membrane was probed with either mouse anti-Ply (1/1000 dilution) or mouse anti-LytA (1/2000 dilution) polyclonal antisera, which was detected with an IRDye 800CW goat anti-mouse IgG (LI-COR). The blot was visualized using the Odyssey imaging system.
Haemolysis assay
A haemolysis assay was used to confirm the haemolytic activity of pneumolysin as described previously [27] . The parent Rx1 strain, Rx1[ermR/ LytA] and the vaccine strain Rx1[PdT/ LytA (preirradiation) were grown to approximately 2 × 10 8 CFU/ml. Three milliliters aliquots of the samples were French pressed at 12000 psi to obtain supernatants for use in the assay.
Ethics statement
Animal experimentation was carried out in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7th edition [2004] and 8th edition [2013] ) and the South Australian Animal Welfare Act 1985. The protocol was approved by the Animal Ethics Committee at The University of Adelaide (Approval numbers S-2010-001 and S-2013-053).
Intranasal sepsis model
Wild-type (WT) C57BL/6 mice (5-6 weeks old) were supplied by Laboratory Animal Services at The University of Adelaide, South Australia. μMT mice (5-6 weeks old) were originally obtained from H. Korner (Menzies Institute for Medical Research, University of Tasmania, Australia) and bred in-house at the University of Adelaide Animal Facility. Mice were first anaesthetized intraperitoneally (IP) with pentobarbital sodium (Nembutal; Ilium) at a dose of 66 μg/g of body weight. The anaesthetized mice then received the γ -PN vaccine by gently applying 30 μl (∼1 × 10 8 CFU equivalents per dose) intranasally (IN) to the nostrils. Control mice received PBS. Mice were immunized IN twice at 2-week intervals. Sera were collected from the mice by submandibular bleeding 1 week after the last immunization. A week later thereafter, mice were challenged IN (as described above) with strains D39 (1 × 10 6 CFU in 30 μl) or P9 (5 × 10 6 CFU in 30 μl). Infected mice were then monitored for up to 21 days to determine the number of days until they were moribund.
Intranasal pneumonia model
For the pneumonia model, immunization and challenge procedures were essentially the same as described above, except that mice were challenged IN with strain EF3030 (1 × 10 7 CFU in 30 μl). Four days post challenge, mice were euthanized and the nasal wash and homogenized nasopharyngeal tissue and lung tissue were plated for CFU recovery as described previously [28] . Total CFU in the nasopharynx includes the CFU from the nasal wash and nasal tissue combined.
Intranasal colonization model
For the colonization model, un-anaesthetized C57BL/6 mice were infected with EF3030 by gently restraining the mice and applying 10 μl (1 × 10 7 CFU) to the nostrils. Seven days later, mice were euthanized and the nasal wash and nasopharyngeal tissue were harvested and plated for CFU recovery as described above.
IFNγ /IL-17A neutralization in vivo
Two weeks after mice received the second dose of γ -PN vaccine as described above, they were treated with neutralizing monoclonal antibodies (all from BioxCell) to IL-17A or interferon-γ (IFN-γ ) [29] . Mice were administered three IP doses (200 μg in 200 μl PBS per dose) of either anti-IL-17 (17F3), antimouse IgG1 (MOPC21) (isotype control for 17F3), anti-IFNγ (XMG1.2) or anti-rat IgG1 (HRPN) (isotype control for XMG1.2) at day −1 (24 h before the challenge), day 0 (6 h post challenge) and day 2 (48 h post challenge). Mice were challenged IN with D39 as described above and monitored for up to 21 days to determine the number of days until they were moribund.
Measurement of antibody responses
Sera collected from immunized mice were assayed by ELISA to determine pneumococcal surface protein A (PspA)-specific antibody responses as described previously [21] . End point titres are expressed as the reciprocal of the last dilution whose OD value was equal to or more than the cut-off value. The cut-off value was determined by adding 3-fold S.D. to the mean (i.e. mean + 3 S.D.) of the OD values of samples from PBS infected mice (negative controls to determine background levels). We used alkaline phosphatase (AP) conjugated rabbit anti-mouse IgG (Invitrogen) and goat anti-mouse IgA (Zymed) as detecting antibodies.
Splenocyte stimulation
Spleens were harvested 2 weeks after the second IN immunization with γ -PN vaccine and were used for splenocyte stimulation as described previously [30] with a few modifications. To obtain cell suspensions, splenocytes were passed through a 70 μm mesh strainer (BD) and suspended in complete RPMI 1640 (RPMI 1640 with Phenol Red supplemented with 10 % foetal calf serum, 1 % L-glutamine, 1 % streptomycin/penicillin and 0.2 % 2-mercaptoethanol). Red blood cells were then lysed using red blood cell lysis buffer. Splenocytes were plated into 96 well tissue culture plates at a concentration of ∼1.8 × 10 6 cells in 200 μl. Splenocytes were stimulated with 50 μl of complete RPMI containing 1 × 10 6 CFU/ml of γ -PN or MalX antigen (10 μg/ml). Complete RPMI 1640 medium alone served as a control. Seventy-two hours later, cells were collected following centrifugation and used for intracellular cytokine staining.
Lung digestion to retrieve lymphocytes for flow cytometric analysis
Lungs were collected from immunized mice at 24 and 48 h post challenge. The lungs were perfused with ice-cold PBS and subsequently dissected and placed in 1 ml digestion medium [Dulbecco's modified Eagle medium (DMEM) containing sodium pyruvate (Thermo Fisher Scientific) supplemented with 1 % HEPES, 5 % FCS, 1 % penicillin/gentamicin, 2.5 mM calcium chloride, collagenase D (Roche; 1 mg/ml) and DNase (Roche; 40 units/ml)]. Lungs were then finely macerated with surgical scissors and incubated at 37 • C for 1 h (with mixing every 20 min). Samples were then processed to obtain single cell suspensions as described above and subjected to intracellular cytokine staining.
Intracellular cytokine staining and flow cytometry
Lung cell suspensions or splenocytes stimulated with γ -PN were used for intracellular cytokine staining using the protocol described previously [31] . For stains involving Foxp3 detection, cells were permeabilized using the Foxp3/transcription factor staining buffer set (eBioscience), whereas for all other stains the Cytofix/Cytoperm kit (BD) was used, according to respective manufacturers' instructions. Cell surface antigens were stained using the following antibodies: anti-CD3 (APC; Biolegend), anti-CD4 (BV450; eBioscience), anti-CD44 (PE-Cy7, eBioscience), anti-CD44 (FITC, BD), anti-CD103 (PE, eBioscience), anti-CD11a (APC, eBioscience), anti-γ δTCR (PercPcy5.5, Biolegend or PECy7, Biolegend), anti-F4/80 (FITC, BD), anti-Gr1 (PE, BD), anti-CD11b (PECy7, BD) and anti-CD45.2 (Biotin, BD). The following intracellular antibodies were used: anti-IL-17A (BV510, Biolegend), anti-IFN-γ (FITC, eBioscience), anti-IFNγ (PECy7, eBioscience), anti-IL-4 (PE, eBioscience) and anti-Foxp3 (PerCPCy5.5, eBioscience). Biotin-conjugated antibodies were detected using Streptavidin-BV450 (BD). In all cases, dead cells were excluded from analyses using LIVE/DEAD fixable near-infrared dye (Molecular Probes). Cells were acquired using an LSRII flow cytometer (BD) and data were analysed using FlowJo software (TreeStar).
Statistics
Data were analysed using a two-tailed Fisher's exact test, unpaired Student's t test or a Mann-Whitney U test, as appropriate. Results with P-values less than 0.05 were considered statistically significant. Statistical analysis was performed using Graph Pad Prism.
RESULTS
Characterization of the γ -PN vaccine
The γ -PN vaccine (Rx1[PdT/ LytA]) was generated by replacing the ply gene in S. pneumoniae Rx1 with a derivative encoding PdT, and then deleting the lytA gene. PdT is a toxoid derivative of Ply carrying three amino acid substitutions (Asp 385 → asparagine, Cys 428 → glycine and Trp 433 → phenylalanine) that abrogate both the complement activation and cytotoxic properties of the toxin, without affecting immunogenicity [25, 32] . The purpose of deleting lytA was to facilitate large scale culture to high cell densities in vitro, by preventing onset of cellular autolysis in stationary phase. Expression of PdT and deletion of lytA were confirmed by Western blot analysis ( Figure 1A ). Anti-Ply and anti-LytA antibodies detected both LytA and native Ply in D39 (lane 2), the parent strain (Rx1) (lane 3) and the respective purified control proteins (lane 1). As expected, no LytA related bands were detected in lysates of pre-irradiated vaccine strain Rx1[PdT/ LytA] samples (lane 4). In contrast, bands related to Ply were still detectable. Complete absence of haemolytic activity of the final vaccine strain Rx1[PdT/ LytA] (pre-irradiation) was also confirmed by a haemolysis assay ( Figure 1B) . Furthermore, the absence of antibiotic resistant genes in the vaccine strain was confirmed using both gene sequencing and plating on media containing the relevant antibiotic (results not shown).
Immunization with γ -PN provides serotype-independent protection
Considering that γ -PN is derived from the un-encapsulated strain Rx1, we initially investigated whether the vaccine was capable of providing protection against IN challenge by the parental encapsulated (type 2) strain D39. Our data show that intranasal vaccination of mice with γ -PN resulted in a statistically significant increase in survival rate (P = 0.0201) compared with mock-immunized control mice following lethal challenge with S. pneumoniae D39 (Figure 2A ). To investigate whether the vaccine can provide serotype-independent protection, we challenged γ -PN immunized mice with S. pneumoniae P9 (serotype 6A). Similarly, IN vaccination with γ -PN afforded significant protection against P9 challenge (P = 0.0431; Figure 2B ), suggesting that the γ -PN vaccine is capable of providing both serotype-dependent and -independent protection against lethal pneumococcal challenge.
In addition, we examined whether the γ -PN vaccine could provide protection against local infection in the lung. Immunized mice were challenged under anaesthesia with EF3030 (serotype 19F), which causes focal pneumonia but not lethal sepsis [33, 34] and bacterial counts in the lungs and nasopharynx were determined 4 days post challenge. Our data show that vaccination with γ -PN reduced bacterial counts in the lungs (P = 0.0397) when compared with control mice ( Figure 2C ). Although median CFU in the nasopharynx was also slightly lower in γ -PN vaccinated mice, this did not reach statistical significance (Figure 2C) . To further explore whether effects on colonization might contribute to vaccine efficacy, we utilized a colonization model. Vaccinated and control mice were inoculated IN with a lower dose of S. pneumoniae EF3030 without anaesthesia and bacterial counts were determined in the nasopharynx at day 7 post inoculation. Our data indicate that vaccination with γ -PN did not affect nasopharyngeal colonization with EF3030, with a similar number of CFU in the nasopharynx of both vaccinated and control mice ( Figure 2D ).
γ -PN efficacy is dependent on B-cell responses
To elucidate the underlying mechanisms of γ -PN-mediated protection, we examined the role of B-cell responses in acquired immunity to S. pneumoniae. Induction of antibody-initiated complement-dependent killing represents the hosts' major defence mechanism against pneumococcal challenge [1] , and generally current approaches for pneumococcal vaccines rely on the efficacy of B-cell responses [8] . Thus, to evaluate the ability of γ -PN to induce antigen-specific antibody responses, we assayed IgA and IgG responses to PspA, a member of the cholinebinding protein family of S. pneumoniae surface proteins, and a proven protective immunogen [35, 36] . Significant levels of PspAspecific IgA (P = 0.0002) and IgG (P = 0.0241) were detected in sera collected from immunized mice 14 days after the second vaccination, relative to those in PBS treated controls ( Figure 3A) .
Next, to determine whether the vaccine's efficacy is dependent on B-cell responses, μMT mice (B-cell-deficient mice) and WT (C57BL/6) mice were immunized IN with γ -PN and challenged IN with D39, and animals were monitored for a period of 21 days. As shown in Figure 3B , γ -PN-vaccinated WT mice show significant protection against lethal D39 challenge compared with PBS treated controls, as indicated by a significantly greater survival rate (P = 0.0059). In contrast, γ -PN-immunized B-cell-deficient μMT mice did not show protection when compared with PBS treated μMT control mice ( Figure 3B ). This suggests that the protective efficacy of the γ -PN vaccine against sepsis is reliant on B-cell responses. 
IL-17 plays an essential role in the protective efficacy of γ -PN
In addition to B-cell responses, previous studies have demonstrated that both IFN-γ and IL-17 are important components of host defences against S. pneumoniae [30, [37] [38] [39] [40] . Therefore, we investigated whether either of these cytokines contributed to the protective efficacy of the γ -PN vaccine. Mice immunized IN with γ -PN were treated with three doses of neutralizing antibodies to IL-17 or IFN-γ , or isotype control antibodies, at days −1, 0 and 2 post challenge with a lethal dose of D39 and were then monitored for survival ( Figure 4 ). Administration of isotype controls for both IFN-γ ( Figure 4A ) and IL-17 ( Figure 4B ) did not alter the protective efficacy of γ -PN against D39 challenge (P = 0.0354 for anti-IFN-γ isotype control group, P = 0.0018 for anti-IL-17A isotype control group). Importantly, γ -PN induced significant protection in immunized mice despite IFN-γ neutralization (P = 0.0083) when compared with their relative control ( Figure 4A ). However, the reduced survival rate of nonimmunized mice in the IFN-γ treated group compared with the isotype control group was expected due to its known role in primary host defence against pneumococcal challenge [37, 38] .
In contrast with IFN-γ neutralization, γ -PN-induced protection was abolished by IL-17A neutralization ( Figure 4B ). Surprisingly, IL-17A neutralization did not influence the lethality rate of pneumococcal infection in non-immunized mice, which illustrates the role of IL-17A in the secondary immune response. These data demonstrate that the mechanisms of protection elicited by γ -PN immunization are IL-17A dependent and in part IFN-γ dependent.
Vaccination with γ -PN induces CD4 + -independent IL-17 immunity
In general, IL-17 derived from Th17 cells has been reported to be the essential component of antigen-specific memory Tcell responses during pneumococcal infections, particularly for driving the recruitment of macrophages and neutrophils into the nasopharynx to mediate clearance [40] . Th17-driven immunity in anti-pneumococcal vaccination strategies has also been clearly demonstrated, as neutralization of IL-17 was reported to interfere with protection against colonization mediated by mucosal immunization with a whole-cell vaccine [30] . Considering the IL-17-dependent protective responses induced by γ -PN (Figure 4) , we next investigated the mechanism underlying γ -PN-induced IL-17-dependent immunity and examined whether γ -PN induces antigen-specific Th17 cells. To do this, splenocytes were harvested from immunized and control mice and stimulated ex vivo with the γ -PN vaccine or a proven Th17 protective antigen MalX [10] for 72 h. Following stimulation, cells were subjected to intracellular cytokine staining for analysis of T helper cell subsets (Th17, Th1, Th2, Treg). Our data show that stimulation of splenocytes from γ -PN immunized mice did not induce a significant increase in the percentage of Th17, Th1, Th2 or Treg relative to the PBS control following stimulation with either the γ -PN vaccine or MalX antigen ( Figure 5B ). These data suggest that γ -PN does not induce circulating Th17 memory cell responses.
To further investigate the memory responses induced by γ -PN vaccine, we analysed whether IL-17 dependency could be related to tissue resident memory (TRM) cells. TRM cells are a unique memory subset as they reside in sites of infection after initial pathogen clearance, provide the first line of antigen-specific defence upon re-infection, and elicit heightened protection relative to circulating central memory cells [41, 42] . Analysis of lung tissue from γ -PN immunized mice showed that these mice did not induce CD4 + TRM cells [TRM total, gated CD44 hi CD103 + and were also CD11a hi (results not shown)] relative to the PBS control, nor were there differences in the ability of these cells to make IL-17A (TRM IL-17 + ; Figure 5C ). Collectively, these data indicate that vaccination with γ -PN does not elicit CD4 + TRM cell responses.
Considering that we did not detect a significant increase in Th17 or TRM IL-17 + cells, we investigated the possible role of IL-17-producing innate immune cells in γ -PN vaccinated animals. In addition to Th17 cells, non-conventional T-cells such as γ δ [43] and NKT cells [44] located in mucosa have been shown to elicit protective pulmonary IL-17A responses. In particular, γ δT17 has been shown to strongly promote the recruitment of neutrophils during pneumococcal infection [45] . Therefore, we hypothesized that the IL-17A-dependent immunity elicited by γ -PN may be due to heightened γ δT17 responses. To investigate this, we examined γ δT-cells and T effector cell numbers in the lungs of γ -PN immunized mice 24 and 48 h post D39 challenge. γ -PN vaccination did not alter the total number of T effector cells or the relative populations of Th1 or Th17 cells in the lung 24 h post D39 challenge ( Figure 6A) . Similar results were observed at 48 h for total T effector cells and Th17. However, we detected a significant decrease in Th1 cell numbers in γ -PN-immunized mice (P = 0.0452) relative to the PBS-treated controls at 48 h post challenge. In contrast with T effector cells, IN vaccination with γ -PN induced significant changes in γ δT-cell populations in the lung post D39 challenge ( Figure 6B ). Although the total number of γ δT-cells in the lung of vaccinated mice was not significantly different relative to non-immunized mice, our data indicate that IN vaccination with γ -PN specifically enhanced γ δT17 cell numbers in the lungs at 24 h (P = 0.0297) and this was further enhanced at 48 h post challenge (P = 0.0157). Interestingly, we detected a decrease in γ δT1 cell numbers in vaccinated mice at 24 h, leading to a significant difference (P = 0.0267) detected at 48 h relative to the control animals. Overall, these data demonstrate that γ -PN promotes a significant increase in γ δT17 cell responses associated with a significant decrease in Th1 and γ δT1 cells and no difference in the Th17 population. Therefore, our data suggest that γ δT17 cells may be a potential source for IL-17A involved in mediating protective immunity in γ -PN-vaccinated mice. Given that IL-17 is known to have a prominent role in driving the influx of phagocytic cells, we investigated the relative numbers of neutrophils and macrophages in the lungs of γ -PNimmunized mice at 24 and 48 h post D39 challenge ( Figure 6C) . Importantly, the numbers of either cell type remains similar at 24 and 48 h post challenge in γ -PN-immunized mice. In contrast, we detected a significant increase in macrophages in the lungs of PBS control mice between 24 and 48 h post challenge (P = 0.0122). This trend was also apparent for neutrophils although it did not reach statistical significance.
DISCUSSION
In recent years there has been a considerable focus on developing pneumococcal vaccines that are serotype independent, cost ef-fective and capable of providing protective immunity in people of all ages. The success of using γ -irradiation to inactivate bacteria has been demonstrated for Rickettsia [46] , Brucella abortus [20] and Listeria monocytogenes (Lm) [14] . In the present study, we administered γ -irradiated, un-encapsulated pneumococcal whole cells to maximize exposure of clinically relevant antigens in their native form. Moreover, the intranasal route of immunization was chosen to reflect the natural route of exposure to pneumococcus in humans. During the initial stages of pneumococcal colonization of the nasopharynx, the CPS is downregulated and there is increased exposure of cell wall teichoic acids and surface proteins, which facilitate attachment to the mucosa [47, 48] . Thus, intranasal delivery of an un-encapsulated whole-cell vaccine may elicit enhanced immunity towards these sub-capsular structures. γ -Irradiation is also a superior inactivation technique, as it maintains cellular structures and prevents disruption of antigens, which can often occur with alternative heat inactivation methods as shown with Lm [14] and chemical or UV inactivation methods as shown for influenza [49] . We have shown that intranasal immunization with γ -PN provides significant serotype-independent protection against sepsis caused by D39 and P9 and focal pneumonia caused by EF3030.
To investigate the underlying mechanism for serotypeindependent protection induced by γ -PN, we evaluated the role of B-and T-cells in acquired immunity. Lack of protective immunity in vaccinated μMT mice illustrates the significant contribution of B-cell responses. Generally, antibodies against capsular and sub-capsular antigens are important for complement fixation and opsonization in systemic clearance of pneumococci [1] . Thus, our data suggest that humoral immunity induced by γ -PN is critical for the protection observed against sepsis and pneumococcal pneumonia. Furthermore, analysis of sera from γ -PN-immunized mice showed induction of PspA-specific IgG and IgA responses. Humoral responses against PspA are crucial to prevent interference with complement-mediated opsonization, one of PspA's major roles in pneumococcal pathogenesis [1] . Humoral immunity has also been implicated in defence against colonization, although increasing evidence suggests that cellular immunity is more crucial [50] . Indeed, Th17 cell responses have been shown to be important for abrogation of the initial stages of bacterial colonization [30, 51, 52] , and the induction of a Th17 response has also been shown to be an important component for immunity induced by a cholera-toxin adjuvanted whole-cell-based pneumococcal vaccine [30] . In the present study, we showed that IN vaccination with γ -PN did not induce antigen-specific Th17 responses, which is a probable explanation for why we did not observe protection in the EF3030 colonization model. Nevertheless, neutralization experiments showed that IL-17 is important for γ -PN vaccine efficacy.
Interestingly, analysis of lymphocytes from the lungs following D39 challenge revealed that γ -PN immunization resulted in enhanced levels of pulmonary γ δT17 cells. These cells represent one of the major innate sources of IL-17A during infection, which plays critical roles in protection against extracellular pathogens such as S. pneumoniae. In addition, γ δT-cell-deficient mice have low survival rates that were shown to be associated with higher bacterial loads and reduced neutrophilia following pneumococcal infection [45, 53] . IL-17 has also been shown to be crucial for the recruitment of neutrophils and macrophages as part of the host's defence against S. pneumoniae [40] . Therefore, it is feasible that γ -PN immunization may promote neutrophilia through enhanced γ δT17 responses, which combines with opsonizing antibodies to clear pneumococcal infection. Furthermore, although we have shown a clear and prominent role for IL-17 in our vaccine-elicited protection, it also appears that IFN-γ may be playing a more supplementary role, which could explain the decrease in survival rates observed in IFN-γ neutralization studies. Similar to IL-17, IFN-γ has also been found to be involved in the induction of neutrophil chemoattractants to promote neutrophil influx to facilitate protection against S. pneumoniae [37] . Our data indicate that IFN-γ plays a more prominent protective role compared with IL-17 during primary infection.
Nevertheless, although our data illustrate the significantly increased number of γ δT17 cells in the lung of vaccinated animals, other innate IL-17A producers such as NKT cells may also be involved. An emerging concept in γ δT-cell biology is the ability of these cells to adopt 'memory'-like properties. Oral Lm infection induces a subset of protective γ δT-cells that preferentially expand upon oral, but not intravenous Lm reinfection or oral Salmonella infection [54] . Similar observations have also been made in a model of Staphlococcus aureus infection [55] . Furthermore, in imiquimod-induced psoriasis inflammation, γ δT17 cells have been shown to redistribute into non-inflamed skin tissue, are activated more rapidly via IL-1β and accelerate secondary skin inflammation upon re-exposure to imiquimod [56] . In the present study, it is not clear whether γ -PN directly induces 'memory'-like γ δT17 cell responses or whether there is an existence of a γ -PN-induced adaptive response that leads to enhanced γ δT17 recruitment or expansion/sensitivity within the lung. More detailed studies will be required to elucidate the mechanisms of γ -PN-induced γ δT17 cell responses.
Furthermore, immunological analysis of phagocytic cells at 24 and 48 h post D39 challenge showed no difference in total levels of macrophages and neutrophils in γ -PN immunized mice. The stable level of inflammation observed in vaccinated mice could imply that the majority of pneumococci are cleared within 48 h, compared with the increased inflammatory responses in control mice illustrated by the significant increase in phagocytic cells. In general, strong neutrophil influx during pneumococcal infection has been shown to be detrimental, with increased mortality rates in mice [57] . Therefore, rapid bacterial clearance and reduced influx of phagocytic cells may underpin the efficacy of γ -PN vaccine.
In addition, we detected a greater increase in the number of γ δT17 cells in γ -PN-immunized mice at 48 compared with 24 h post challenge. This suggests that γ δ-derived IL-17 could be playing another role in the control of pneumococcal infection apart from promoting neutrophilia. Indeed, IL-17 has been shown to regulate the production of antimicrobial peptides such as βdefensin 2 [58] , which has been reported to work synergistically with lysozymes to inhibit the growth of S. pneumoniae [59] . Thus, IL-17 induced by γ -PN may have also enhanced innate anti-microbial peptide defences against S. pneumoniae. In addition, it has been suggested that promoting IL-17 responses could be beneficial for alleviating the problem of super-infection that occurs between influenza and S. pneumoniae. In particular, IFN-I induced by influenza virus has been reported to compromise IL-17 production by γ δT-cells, thereby exacerbating infection [60] . Therefore, γ -PN-induced γ δT17 cells could also be advantageous in preventing the harmful effects of co-infection with other pathogens. Further experiments are required to fully elucidate the role and significance of γ -PN vaccine-induced IL-17 responses.
Our data also illustrate limited efficacy for γ -PN against nasopharyngeal carriage compared with previous reports using an ethanol-whole-cell pneumococcal vaccine that demonstrated protective efficacy against pneumococcal carriage via antibody independent, Th17-driven immunity [30] . However, experience with pneumococcal conjugate vaccines has shown that elimination of carriage may be a 'double edged sword', whereby the benefits of blockading transmission of strains covered by the vaccine can be offset by facilitating the phenomenon of 'serotype replacement' with other types of pneumococci, or indeed by promoting carriage of other significant bacterial pathogens such as S. aureus [61] . An important additional consideration is that efficacy of previous experimental pneumococcal vaccines targeted for mucosal administration, such as protein combination [12, 62] and whole-cell [22] vaccines, has been dependent on formulation with strong mucosal adjuvants, such as cholera toxin, which are unlikely to be approved for human use. In contrast, the γ -PN vaccine is non-adjuvanted and still elicits significant protection. We propose that γ -irradiation of pneumococcal whole cells is associated with reduced damage to antigenic epitopes which may facilitate the ability of the γ -irradiated whole-cell-based vaccine to be taken up and processed efficiently by antigen presenting cells, leading to the induction of highly effective immune responses. Furthermore, intranasal administration has limited impact on nasal carriage, highlighting its potential application as a vaccine candidate for human use. In addition, intranasal immunization is highly advantageous due to the fact that it is relatively safe, painless, needle free and a more acceptable vaccination approach to the public. It is also easily deliverable and decreases the risk of disease transmission that can occur through the use of syringes [63] .
In summary, the present study describes the development of a non-adjuvanted γ -irradiated whole-cell pneumococcal vaccine that elicits serotype-independent protection against both pneumococcal sepsis and focal pneumonia. We show that the efficacy of our γ -PN vaccine is dependent on both B-cell and IL-17 responses. In particular, we are the first, to our knowledge, to demonstrate the induction of vaccine-induced innate-derived IL-17-responses. The induction of γ δT17 cells by γ -PN vaccination may provide a strategic immunization approach to protect, not only against single pneumococcal challenge but also against super-infection by other pathogens.
CLINICAL PERSPECTIVE
• S. pneumoniae (the pneumococcus) is the leading cause of morbidity and mortality worldwide. Currently available vaccines provide protection against a limited number of serotypes. The aim of the study was to generate a pneumococcal vaccine with the ability to provide broader 'universal' immunity against a much wider range of serotypes. 
